吉利德科学 GILD 深 沪
等待开盘 02-07 09:30:00 美东时间
149.895
+0.525
+0.35%
华盛通- 最 高150.50
- 今 开149.69
- 成交量 208.30万股
- 最 低 116.88
- 昨 收 149.37
- 总市值 1.88亿
- 52周最高 150.50
- 市盈率 静 30.39
- 换手率 166.11%
- 52周最低 0.00
- 委 比 46.34%
- 总股本 0.01亿
- 历史最高 150.50
- 量 比 1.36
- 振 幅 22.51%
- 历史最低 0.00
- 每 手 1
- 风险率 8.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Approves Label Update For Gilead's Kite's Yescarta
– Limitations of Use Removed for Rare and Aggressive Form of non-Hodgkin Lymphoma Based on Manageable Safety Profile with No New Safety Signals Identified –
02-06 21:31
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.
01-28 18:51
The Insider Report: Bulls on Parade to Start 2026
Market Overview It was a strong week for stocks with the consumer discretionary...
01-12 05:44
Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes
Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.
2025-12-23 02:46
US Medicaid Program Will Hit Swiss Wallets Hard, Roche CEO Says
Roche CEO predicts higher drug costs in Switzerland due to U.S. government's deals with pharmaceutical companies.
2025-12-22 21:43
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
Healthcare ETFs stay resilient as Big Pharma agrees to Medicaid drug price cuts. Here's what is cushioning ETFs despite pricing pressure.
2025-12-20 04:17
MHRA Approves Lenacapavir For The Prevention Of Sexually Transmitted HIV-1 Infection
https://www.gov.uk/government/news/mhra-approves-lenacapavir-for-the-prevention-of-sexually-transmitted-hiv-1-infection
2025-12-19 23:14
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and Medicare payment reforms.
2025-12-18 23:14
Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
2025-12-16 01:15
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC data and key 2026 milestones.
2025-12-13 02:35
